SLC5A2 and heart failure: Through the subgroup analysis we found that SGLT2 inhibitors significantly reduced the composite endpoint of the first hospitalization for heart failure or cardiovascular death in patients with HFpEF no matter using a left ventricular ejection fraction > 50%, or > 40% as the cut-off point for HFpEF.